Proven first-line therapy

INVANZ is indicated for the treatment of patients, including pediatric patients aged 3 months to 17 years, with the following moderate to severe infections caused by susceptible isolates of  microorganisms, as well as initial empiric therapy prior to the identification of causative organisms.

• Complicated intra-abdominal infections
• Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis.
• Community-acquired pneumonia
• Complicated urinary tract infections including pyelonephritis
• Acute pelvic infections, including postpartum endomyometritis, septic abortion, and postsurgical gynecologic infections